$1.27
-0.03 (-2.27%)
Open$1.28
Previous Close$1.30
Day High$1.35
Day Low$1.27
52W High$6.75
52W Low$1.05
Volume—
Avg Volume9.3K
Market Cap2.28M
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,568.5% upside
Current
$1.27
$1.27
Target
$21.19
$21.19
$14.35
$21.19 avg
$22.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 842.6K | 775.9K | 707.6K |
| Net Income | 53.5K | 41.0K | 38.8K |
| Profit Margin | 6.3% | 5.3% | 5.5% |
| EBITDA | 84.6K | 70.9K | 63.0K |
| Free Cash Flow | 39.3K | 30.9K | 34.5K |
| Rev Growth | +2.0% | +16.5% | +21.7% |
| Debt/Equity | 0.16 | 0.21 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |